Valentin Harter

1.4k total citations
29 papers, 738 citations indexed

About

Valentin Harter is a scholar working on Surgery, Oncology and Radiation. According to data from OpenAlex, Valentin Harter has authored 29 papers receiving a total of 738 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Surgery, 12 papers in Oncology and 6 papers in Radiation. Recurrent topics in Valentin Harter's work include Bladder and Urothelial Cancer Treatments (8 papers), Advanced Radiotherapy Techniques (6 papers) and Cancer Diagnosis and Treatment (5 papers). Valentin Harter is often cited by papers focused on Bladder and Urothelial Cancer Treatments (8 papers), Advanced Radiotherapy Techniques (6 papers) and Cancer Diagnosis and Treatment (5 papers). Valentin Harter collaborates with scholars based in France, Luxembourg and United States. Valentin Harter's co-authors include D. Peiffert, C. Charra-Brunaud, M. Delannes, Christine Haie-Méder, Philippe Quétin, Laurence Thomas, Christine Kerr, B. Castelain, Stéphane Culine and Christian Pfister and has published in prestigious journals such as Journal of Clinical Oncology, Bioinformatics and The Journal of Urology.

In The Last Decade

Valentin Harter

26 papers receiving 732 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Valentin Harter France	13	386	287	158	126	110	29	738
Pierre Maroun France	13	289 0.7×	288 1.0×	135 0.9×	131 1.0×	34 0.3×	37	591
Shyam K. Shrivastava India	16	328 0.8×	420 1.5×	217 1.4×	228 1.8×	79 0.7×	31	918
Robyn Banerjee Canada	13	191 0.5×	204 0.7×	140 0.9×	182 1.4×	27 0.2×	43	566
Izumi Koike Japan	16	160 0.4×	132 0.5×	201 1.3×	198 1.6×	111 1.0×	50	729
Melis Gültekin Türkiye	11	171 0.4×	166 0.6×	118 0.7×	105 0.8×	24 0.2×	75	487
G.A. Rawlings Canada	15	494 1.3×	440 1.5×	138 0.9×	143 1.1×	55 0.5×	21	876
Yoshihito Nomoto Japan	15	196 0.5×	81 0.3×	140 0.9×	211 1.7×	45 0.4×	49	532
Kanjana Shotelersuk Thailand	10	136 0.4×	82 0.3×	174 1.1×	86 0.7×	110 1.0×	32	520
Diane C. Ling United States	17	329 0.9×	70 0.2×	209 1.3×	239 1.9×	23 0.2×	46	737
Thongbliew Prempree United States	19	390 1.0×	294 1.0×	254 1.6×	207 1.6×	66 0.6×	57	866

Countries citing papers authored by Valentin Harter

Since Specialization

Citations

This map shows the geographic impact of Valentin Harter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Valentin Harter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Valentin Harter more than expected).

Fields of papers citing papers by Valentin Harter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Valentin Harter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Valentin Harter. The network helps show where Valentin Harter may publish in the future.

Co-authorship network of co-authors of Valentin Harter

This figure shows the co-authorship network connecting the top 25 collaborators of Valentin Harter. A scholar is included among the top collaborators of Valentin Harter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Valentin Harter. Valentin Harter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Großhennig, Anika, Valentin Harter, Angela Mastronuzzi, et al.. (2025). Cancer risk in carriers of TP53 germline variants grouped into different functional categories. JNCI Cancer Spectrum. 9(1). 1 indexed citations

Rouleau, Étienne, Isabelle Soubeyran, Véronique Haddad, et al.. (2024). 768P Reclassification and variant distribution in the GINECO GREAT study of ovarian cancer patients: Insights into HRD status. Annals of Oncology. 35. S580–S581. 1 indexed citations

Leroy, Éric, et al.. (2024). Time to reconsider the use of synthetic mesh in immediate prepectoral implant-based breast reconstruction: Impact of their use on short-term outcomes. European Journal of Surgical Oncology. 51(3). 108780–108780.

Culine, Stéphane, Valentin Harter, Clémentine Krucker, et al.. (2023). Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Cancers. 15(6). 1742–1742. 6 indexed citations

Allory, Yves, Stéphane Culine, Clémentine Krucker, et al.. (2023). Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial. The Journal of Urology. 211(4). 564–574. 5 indexed citations

Pfister, Christian, Gwénaëlle Gravis, Aude Fléchon, et al.. (2023). Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.. Journal of Clinical Oncology. 41(17_suppl). LBA4507–LBA4507. 6 indexed citations

Pfister, Christian, Gwénaëlle Gravis, Aude Fléchon, et al.. (2021). 652O Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial. Annals of Oncology. 32. S678–S678. 7 indexed citations

Pfister, Christian, Gwénaëlle Gravis, Aude Fléchon, et al.. (2020). Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. European Urology. 79(2). 214–221. 150 indexed citations

Culine, Stéphane, Gwénaëlle Gravis, Aude Fléchon, et al.. (2020). Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses.. Journal of Clinical Oncology. 38(6_suppl). 437–437. 14 indexed citations

10.

Mariette, C., Florence Renaud, Guillaume Piessen, et al.. (2018). The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers. BMC Cancer. 18(1). 139–139. 13 indexed citations

11.

Castéra, Laurent, Valentin Harter, Etienne Müller, et al.. (2018). Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families. Genetics in Medicine. 20(12). 1677–1686. 49 indexed citations

12.

Marchal, C., et al.. (2014). Efficacité et sécurité de la technique de radiothérapie mammaire avec complément d’irradiation concomitant : analyse de 121 cas traités à l’institut de cancérologie de Lorraine. Cancer/Radiothérapie. 18(3). 165–170. 3 indexed citations

13.

Peiffert, D., et al.. (2014). A case–control study of patients with squamous cell carcinoma of the oral cavity and oropharynx treated with pulsed-dose-rate brachytherapy. Brachytherapy. 13(6). 597–602. 12 indexed citations

14.

Leroux, Agnès, et al.. (2014). Tumeur de la Granulosa de l’ovaire : étude rétrospective à propos de 17 cas. Gynécologie Obstétrique & Fertilité. 42(5). 331–333. 2 indexed citations

15.

Harlé, Alexandre, et al.. (2013). Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: Correlation with clinicopathological criteria. Oncology Reports. 29(3). 1043–1052. 34 indexed citations

16.

Gräff, P., Valentin Harter, V. Marchesi, et al.. (2013). Evaluation of the Block Matching deformable registration algorithm in the field of head-and-neck adaptive radiotherapy. Physica Medica. 30(3). 301–308. 16 indexed citations

17.

Chrétien, Anne-Sophie, Alexandre Harlé, Marie Husson, et al.. (2012). Optimization of routine KRAS mutation PCR‐based testing procedure for rational individualized first‐line‐targeted therapy selection in metastatic colorectal cancer. Cancer Medicine. 2(1). 11–20. 15 indexed citations

18.

Charra-Brunaud, C., Valentin Harter, M. Delannes, et al.. (2012). Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: Results of the French STIC prospective study. Radiotherapy and Oncology. 103(3). 305–313. 281 indexed citations

19.

Marchesi, V., et al.. (2012). Comparaison dosimétrique des radiothérapies conformationnelles avec modulation d’intensité par faisceaux statiques et RapidArc® des cancers du col. Cancer/Radiothérapie. 16(3). 209–214. 23 indexed citations

20.

Dubray, Bernard, V. Beckendorf, S. Guérif, et al.. (2011). Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).. Journal of Clinical Oncology. 29(15_suppl). 4521–4521. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact